Cognition Therapeutics
Pittsburgh
About Cognition Therapeutics
Cognition Therapeutics, Inc. is focused on the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of disease targets, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the unique combination of biological expertise around these targets, including proprietary assays that emphasize functional responses and proprietary medicinal chemistry that insures novel, high quality small-molecule drug candidates.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $207.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Aug 2025)
- Ticker: nasdaq:CGTX
- Website: cogrx.com
- Phone: (412)481-2210
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cognition-therapeutics-27138 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.